Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other financing activities: 2021-2025

  • Akebia Therapeutics' Other financing activities fell 91.60% to $63,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $41.3 million, marking a year-over-year change of. This contributed to the annual value of $1.3 million for FY2024, which is N/A change from last year.
  • Per Akebia Therapeutics' latest filing, its Other financing activities stood at $63,000 for Q1 2025, which was down 87.93% from $522,000 recorded in Q3 2024.
  • Akebia Therapeutics' 5-year Other financing activities high stood at $44.8 million for Q1 2021, and its period low was $63,000 during Q1 2025.
  • Moreover, its 2-year median value for Other financing activities was $522,000 (2024), whereas its average is $445,000.
  • Data for Akebia Therapeutics' Other financing activities shows a maximum YoY plummeted of 91.60% (in 2025) over the last 5 years.
  • Quarterly analysis of 4 years shows Akebia Therapeutics' Other financing activities stood at $44.8 million in 2021, then decreased by 10.68% to $40.0 million in 2022, then reached $522,000 in 2024, then tumbled by 91.60% to $63,000 in 2025.
  • Its Other financing activities was $63,000 in Q1 2025, compared to $522,000 in Q3 2024 and $750,000 in Q1 2024.